Abrdn Healthcare Opportunities Fund
THQ
New York Stock Exchange- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Daniel R. Omstead
- Sector
- Financial Services
- Industry
- Asset Management
- Address
- 100 Federal Street Philadelphia PA United States of America 19103
- IPO Date
- Jul 29, 2014
- CIK
- 0001604522
- Website
- teklacap.com
- Similar Companies
- Business
- abrdn Healthcare Opportunities Fund (NYSE: THQ) is a non-diversified, closed-end management investment company that seeks current income and long-term capital appreciation through investments in U.S. and non-U.S. healthcare companies. The Fund normally invests at least 80% of its Managed Assets in equity securities, debt securities and pooled investment vehicles of companies engaged in the healthcare industry, including biotechnology, pharmaceuticals, diagnostics, managed healthcare, medical devices, healthcare services and life sciences; its portfolio emphasizes securities from issuers with strong market positions, proven management and technological expertise, with top holdings including Eli Lilly and Co., AbbVie Inc., Abbott Laboratories and Merck & Co Inc. Launched in 2015 under Tekla Capital Management LLC prior to its integration into abrdn Inc., the Fund is headquartered in Boston, Massachusetts, and trades on the New York Stock Exchange. abrdn Healthcare Opportunities Fund operates globally with a focus on public equity and fixed income markets in the healthcare sector, benchmarking performance against the S&P 1500 Healthcare Index and S&P 500 Index, while targeting income-oriented investors through its monthly dividend distributions, which were most recently declared at $0.18 per share in October 2025. In recent developments, the Fund underwent a significant rebranding and structural evolution under the abrdn umbrella following its prior association with legacy asset management entities, reflecting a shift toward enhanced global capabilities, expanded research resources and updated investment strategies aligned with evolving healthcare trends; additionally, in March 2024, abrdn announced an investment team update across its healthcare-focused funds including THQ, alongside consistent monthly dividend payments that underscore ongoing commitment to shareholder income amid market challenges such as high interest rates.